Advances in genetic testing are aiding in prognosis and therapeutic decision making in colorectal cancer (CRC). At the 2019 annual meeting of the Hematology/Oncology Pharmacy Association, Amber Draper, PharmD, discussed the application of molecular biomarkers such as microsatellite instability (MSI) and KRAS and BRAF mutations in the treatment of both early and late-stage disease.
“Colorectal cancer is a genetically diverse disease that requires assessment of genetic and mutational markers